Alzheimer's Research & Therapy | Volume 5 Issue 1

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

cover

	Volume 5 Issue 1
	Comment
	Editorial The C9ORF72 mutation brings more answers and more questions Bruce L Miller Alzheimer's Research & Therapy 2013, 5:7 (18 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Bruce Miller, Guest Editor of the special series: The new FTD mutation on chromosome 9, discusses the C9ORF72 mutation associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis.
	Review
	Review Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss, Sandra E Black Alzheimer's Research & Therapy 2013, 5:1 (9 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lam and colleagues review the different subtypes of Alzheimer's disease (AD), discussing the need for personalized AD medicine and the potential for targeting specific AD subtypes in future clinical trials.
	Review Alcohol-related dementia: an update of the evidence Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.
	Report
	Meeting report Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery Rachel F Lane, Penny A Dacks, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2013, 5:5 (4 February 2013) Abstract \| Full text \| PDF \| PubMed
	Research
	Research Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application Carina Wattmo, Erik Jedenius, Kaj Blennow, Åsa K Wallin Alzheimer's Research & Therapy 2013, 5:2 (3 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary High compliance to treatment with cholinesterase inhibitor galantamine was seen in a clinical study of patients with Alzheimer's disease (AD), with plasma concentration correlating strongly to dosage.
	Research ¹⁸F-florbetaben Aβ imaging in mild cognitive impairment Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
	Research Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte, David Wilkinson Alzheimer's Research & Therapy 2013, 5:6 (21 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Combination treatment with memantine added to donepezil provides significant benefits to moderate and moderate-to-severe Alzheimer's disease patients in meta-analyses of data from two 24-week, randomised, double-blind, placebo-controlled trials.
	Research Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell, Randi Fain Alzheimer's Research & Therapy 2013, 5:12 (21 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Donepezil 23 mg/day provides significant benefits over 10 mg/day across a range of cognitive domains in patients with moderate to severe Alzheimer's disease, especially in the language domain.